Skip to contentM
Myriad Genetics Inc
M
MYGNMyriad Genetics Inc Q3 2025 · 10-Q
Revenue$205.70M$205.70M−3.6% vs Q3 2024 Net Income-$27.40M-$27.40MN/M vs Q3 2024 EPS Diluted-$0.29-$0.29N/M vs Q3 2024 Gross Profit$143,800,000−4.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Myriad Genetics Inc · CIK 899923 · Engraved from SEC EDGAR
Operating Cash Flowderived$21,100,000+2,914.3% Margins · derivedGross margin69.9%−0.3 pt vs Q3 2024
Operating margin-11.3%−2.0 pt vs Q3 2024
Net margin-13.3%−3.0 pt vs Q3 2024
ended Sep 30, 2025 · filed Nov 4, 2025 · 35 d after period end